Evidence map›Paper›PMID 27208366›Full record

ArticleDiabetes care2016

Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes.

Boris Kovatchev, Claudio Cobelli

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04730882 (Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults), which is not on this map. Cited by 112 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
23.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04730882 completednot on this mapstarted 2021, after this paper: background citation

Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults

TypeobservationalSponsorUniversity of VirginiaRan2021 to 2024Enrolled36ConditionsType 1 Diabetes, Hyperglycemia, PostprandialArmsMixed Meal
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 2 syntheses or guidelines pooled it, 246 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Assessment of Glucose Control Metrics by Discriminant Ratio.Diabetes technology & therapeutics · 2020
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Boris KovatchevCenter for Diabetes Technology, University of Virginia, Charlottesville, VA.
Claudio CobelliDepartment of Information Engineering, University of Padova, Padova, Italy cobelli@dei.unipd.it.
University of Padua · ITUniversity of Virginia · US

Funding

Improving intensive insulin therapy through the personalization of data-driven decision support system to patients’ goals and preferences and its adaptation to long term health needsR01DK051562 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI MARC D BRETON, Chiara Fabris · 1996 to 2026
$9.4M
NIDDK NIH HHS R01 DK051562
6 · The paper itself

Abstract

Glucose control, glucose variability (GV), and risk for hypoglycemia are intimately related, and it is now evident that GV is important in both the physiology and pathophysiology of diabetes. However, its quantitative assessment is complex because blood glucose (BG) fluctuations are characterized by both amplitude and timing. Additional numerical complications arise from the asymmetry of the BG scale. In this Perspective, we focus on the acute manifestations of GV, particularly on hypoglycemia, and review measures assessing the amplitude of GV from routine self-monitored BG data, as well as its timing from continuous glucose monitoring (CGM) data. With availability of CGM, the latter is not only possible but also a requirement-we can now assess rapid glucose fluctuations in real time and relate their speed and magnitude to clinically relevant outcomes. Our primary message is that diabetes control is all about optimization and balance between two key markers-frequency of hypoglycemia and HbA1c reflecting average BG and primarily driven by the extent of hyperglycemia. GV is a primary barrier to this optimization, including to automated technologies such as the "artificial pancreas." Thus, it is time to standardize GV measurement and thereby streamline the assessment of its two most important components-amplitude and timing.

Indexed as

BiomarkersBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Glucagon-Like Peptide-2 ReceptorGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsModels, TheoreticalPeptidesPrincipal Component AnalysisRisk AssessmentRisk FactorsBiomarkersBlood GlucoseGlucagon-Like Peptide-2 ReceptorGlycated HemoglobinHypoglycemic AgentslixisenatidePeptides

Identifiers

PMID27208366
PMCPMC4806774
OpenAlexW2302984431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.